Core Insights - Ignite Proteomics LLC has entered a research collaboration with Inova Health to utilize its Reverse Phase Protein Array (RPPA) technology for analyzing tumor samples from patients with late-stage gastrointestinal cancers [1][2] - The collaboration aims to generate actionable biomarker data from up to 600 tumor samples, focusing on various cancer-relevant drug target proteins [2][3] - This partnership is expected to enhance precision medicine approaches and contribute significantly to Ignite's revenue in 2025 [3] Company Overview - Ignite Proteomics is a subsidiary of IMAC Holdings, specializing in pathway-level protein analytics to guide precision oncology [4] - The company operates a CLIA-certified, CAP-accredited laboratory and its clinical RPPA assay quantifies 32 phospho- and total-protein biomarkers from small biopsy samples [4] Collaboration Details - The results from the RPPA analysis will be provided to Inova's Molecular Tumor Board to assess therapy response and resistance based on specific protein or phosphor-protein levels [2][3] - The collaboration is seen as a significant advancement in providing direct measures of protein drug target activity, which is not obtainable through genomic analysis [3]
Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers